Sanofi and Bausch Health Companies Inc.: SG&A Spending Patterns Compared

Sanofi vs. Bausch: SG&A Spending Showdown

__timestampBausch Health Companies Inc.Sanofi
Wednesday, January 1, 201420263000008565000000
Thursday, January 1, 201526827000009496000000
Friday, January 1, 201628100000009592000000
Sunday, January 1, 2017258200000010164000000
Monday, January 1, 201824730000009934000000
Tuesday, January 1, 201925540000009883000000
Wednesday, January 1, 202023670000009390000000
Friday, January 1, 202126240000009555000000
Saturday, January 1, 2022262500000010539000000
Sunday, January 1, 2023291700000010765000000
Monday, January 1, 20249183000000
Loading chart...

Data in motion

SG&A Spending Patterns: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. Sanofi and Bausch Health Companies Inc. offer a fascinating comparison in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Over this period, Sanofi consistently outspent Bausch Health, with an average SG&A expense nearly four times higher. Notably, Sanofi's SG&A expenses peaked in 2023, reaching approximately 10.8 billion, marking a 26% increase from 2014. In contrast, Bausch Health's expenses showed a more modest growth, with a 44% increase over the same period, peaking at around 2.9 billion in 2023. This disparity highlights Sanofi's aggressive market strategies and expansive operations compared to Bausch Health's more conservative approach. As the industry faces new challenges, these spending patterns provide insights into each company's strategic priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025